•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
ST. JOHN'S, NL, June 5, 2026 /CNW/ - Aurion Resources Ltd. (TSXV: AU) (OTCQX: AIRRF) ("Aurion") is pleased to announce that, at its special meeting (the...
The article explains how property conditions, inspection services, and home size can influence home inspection costs for buyers.BOURBONNAIS, Ill., June 5, 2026 /PRNewswire/ --...
/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/SASKATOON, SK, June 4, 2026 /CNW/ - Wescan Goldfields Inc. (TSXV: WGF) ("Wescan"...
SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Prologis, Inc. (NYSE: PLD) will host a webcast and conference call with senior management to discuss its...
RALEIGH, N.C., June 04, 2026 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE:HIW) has executed a recast of a $150 million unsecured bank term loan by extending the maturity date from May 2027 to June 2031, inclusive of two one-year extension options that are exercisable at the Company’s option assuming no defaults have occurred.
MIDLAND, TX, June 04, 2026 (GLOBE NEWSWIRE) -- Mexco Energy Corporation (NYSE American: MXC) announced today that its Board of Directors declared a regular annual cash dividend of $0.10 per common share. The dividend is payable June 30, 2026 to the stockholders of record at the close of business on June 15, 2026.